News & Updates

News, highlights and updates from MMCV, Inc. & MMC Ventures | 2025 | Q3

Since launching MMC Ventures, we’ve remained committed to a bold, focused approach—delivering real results that reflect our vision and investment thesis. By targeting opportunities that drive value and advance health equity, we’re backing ventures capable of scalable impact. As you’ll see in the updates below, this mission-driven model is delivering results. One of our earliest bets - the transformation of underutilized campus space at Meharry Medical College into a high-value clinical pathology lab—now has a post-money valuation of $11.3 million.

That win didn’t just create value—it unlocked momentum.

Now managing approximately $35 million in assets across direct investments and integrated health platforms, we are actively building a pipeline of ventures designed for scalability. From acquiring clinical assets that reinforce Meharry’s mission to funding innovative technology and care models, we strive to elevate growth-phase companies into market leaders that deliver meaningful impact and long-term value.

MOMENTUM THAT WE CAN MEASURE

MMCV Negotiated Deal Creates Milestone Success for Meharry Medical College

In May, we announced the news of a transformative deal, spearheaded and negotiated by the MMCV team. Through our leadership, Meharry Medical College announced the acquisition of eight medical clinics previously owned by Sanitas Medical Centers in a joint venture with BlueCross BlueShield of Tennessee. Now integrated into the Meharry Health Network, managed by Meharry Health Solutions, these clinics serve over 25,000 patients across Nashville and Memphis, expanding both patient care experiences and training opportunities for future healthcare leaders while establishing a profit center with significant growth potential.

The acquisition marks a pivotal moment for the MMCV team, exemplifying the kind of strategic, high-impact opportunities we identify and execute. It also represents a significant advancement in Meharry’s mission—under the leadership of Dr. James E. K. Hildreth—to deliver equitable, community-focused healthcare and expand access to high-quality medical services. Beyond this milestone, the transaction lays critical groundwork for future innovations aimed at elevating the college’s legacy and expanding its portfolio of mission-aligned ventures.

Meharry Medical College Consolidated Clinical Laboratories (MMCCCL) Makes Strides in Clinical Innovation

COLA Accreditation Achieved

MMCCCL recently achieved COLA accreditation, provided by a private, CMS-approved laboratory accreditation organization that supports laboratories in improving testing quality, ensuring regulatory compliance, and promoting operational excellence through inspections, quality standards, and ongoing monitoring. Earning COLA accreditation affirms our lab’s commitment to high standards of performance, patient care, and continuous improvement.

Molecular Expansion and MolDX Readiness

MMCCCL is discussing ways to strategically expand its molecular diagnostics capabilities to include PCR infectious disease panels, next-generation sequencing (NGS), and LC/MS-based toxicology. As part of our implementation process, we are preparing Z-Code submissions and conducting technical assessments to ensure compliance with MolDX guidelines.

This is not just about what we’ve built -it’s about what we’re building.

MMC Ventures: Driving Healthcare Innovation

MMC Ventures Fund I is progressing toward its $100M fundraising target. Early milestones include:

Secured Meharry Medical College with a $5M anchor commitment
Invested in restorative health, MedTech, and telehealth digital platforms.
Expanded its Advisory Board by appointing:
- Fred Lowery, SVP at Thermo Fisher Scientific (also added to the Investment Committee)
- Keith Coleman, Venture Capitalist and Family Office Executive

As we continue to advance discussions with new institutional LPs, we’re building on a foundation of trust, operational integration, and measurable value.

Explore how our latest investments —such as Heal90 and Shotel— demonstrate the power of aligned capital, clinical strategy, and community impact.

Heal90, Inc.

Heal90, Inc., a lifestyle medicine company focused on reversing chronic metabolic diseases, closed 2024 with transformative growth across its clinical model, B2B adoption, and academic-health system partnerships. The company expanded the number of lives under contract from 2,200 to 10,000—representing $925,000 in new projected annual revenue—and launched a restructured pricing model to support long-term revenue scalability. With retention rates rising from 52% to 75% after 90 days, Heal90 continues to prove its ability to deliver sustainable engagement and measurable outcomes.

In tandem, the company broadened its product offering from men-only to include women, rolled out 24 live educational sessions across five foundational health domains, and launched a pilot program for employers that is already driving a 40% increase in pipeline conversion. These initiatives position Heal90 to more than double its B2B footprint to 22,000 covered lives and add 3,000 new B2C participants in 2025.

Heal90’s strategic integration into the Meharry Health Network further sets it apart as a high-value, institutional-grade platform. This includes:

A provider referral model with Meharry Medical Group (MMG), expected to generate $1.25M for Heal90 and $6.6M in incremental revenue for MMG.
Training MMG clinicians in lifestyle medicine, embedding Heal90’s protocols into standard care.
Co-developing a lifestyle medicine curriculum through MMC’s School of Medicine, positioning MMC to become the first HBCU with ACLM-certified education.
Collaborating with MMC’s computational sciences group on data and outcomes research.

With $1.75M in active pipeline, a recurring revenue model with proven lifetime value, and strong early outcomes—including normalization of blood pressure and glucose in over 75% and 56% of participants, respectively—Heal90 is delivering measurable outcomes with a scalable, revenue-generating model. Backed by said scalable care model, new leadership hires, and expanding digital infrastructure, Heal90 is well-positioned for accelerated growth in 2025 and beyond.

Shotel Medical, Inc.

Shotel Medical, Inc., the New Orleans-based orthopedic innovator behind the Shotel Nail and one of our seed investments, is celebrating a strong 2025 marked by institutional traction, surgeon engagement, and heightened market visibility. With support from MMC Ventures Fund I, the company has expanded its training program, achieved approvals at three additional hospital systems, Resurgens Orthopedics (Fayetteville, GA), Capital Health Hopewell (Pennington, NJ), and Mercy Clinic Orthopedics (Galena, KS), and surpassed $10,000 in monthly recurring revenue.

Through national conference participation, including the American College of Foot and Ankle Surgeons and the New York State Podiatry Medical Association Conference, and ongoing cadaveric training labs, Shotel has onboarded a growing network of foot and ankle surgeons trained in its minimally invasive fusion procedure. The Shotel Nail remains the only FDA-cleared curved intramedullary device for tibiotalar arthrodesis, offering early weight-bearing and biomechanical advantages that improve patient outcomes and reduce recovery time.

Now launching its $3 million Seed round, Shotel aims to accelerate adoption, scale its sales and training model, and bring four additional lower-extremity devices through FDA clearance and IP protection. With a $1.3 billion addressable market and a 100% reorder rate among trained surgeons, Shotel continues to redefine standards in orthopedic fusion with surgical precision and commercial momentum.

We’re not standing still – we’re building on real traction and proven wins, demonstrating how our model works. With each new venture, we grow stronger, smarter, and more prepared for what’s ahead.

615.866.0025 | info@mmcvinc.com | 1005 D. B. Todd Jr. Boulevard Nashville, Tennessee 37208